Impact of Rituximab in the Clinical Outcomes of Hairy Cell Leukemia: A Single-Institution Analysis

Conclusions: In this study, we report a large, single-institution dataset of HCL and HCLv patients with long-term follow-up. The addition of rituximab improved the PFS in patients with HCL in the first-line and relapse settings and should be considered as a reasonable addition in the therapy for HCL even in the absence of randomized trials.DisclosuresChavez: Humanigen: Consultancy; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Merck: Research Funding; Kite: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Speakers Bureau.

Source: Blood - November 21, 2018 Category: Hematology Authors: Kerr, D. A., Gonter-Aubin, K., Rose, A., Nguyen, T. L., Pinilla Ibarz, J., Chavez, J. C. Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies Source Type: research